ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2068

All-Cause Mortality in a Systemic Lupus Erythematosus Cohort

Michelle Petri1, Joseph Levy2, Urbano Sbarigia3 and Daniel W. Goldman1, 1Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 2Bloomberg School of Public Health, Baltimore, MD, 3Johnson & Johnson, Beerse, Belgium

Meeting: ACR Convergence 2022

Keywords: Mortality, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Multiple studies have documented that patients with SLE have a higher all-cause mortality. Active disease contributes to early deaths with later deaths more likely due to cardiovascular disease and malignancy. In this study we present the pattern of mortality in a single long-term, prospective cohort using death certificates to document cause of death.

Methods: The cohort consists of 2,238 patients (92% female, 52% Caucasian, 39% African-American) with 92% from Maryland and surrounding states (MD 71%, VA 9%, PA 7%, DE 3%, WV 1%, DC 1%). Death records for 1,288 patients lost to follow up prior to 2020 were obtained from the National Death Index (NDI) at the Center for Disease Control (Atlanta, GA). The NDI identified 11,369 death records from 1985 to 2019 as possible matches based on name, gender, race, and date of birth. Primary and secondary causes of death were provided for the best match for each patient. The causes of death were based on CDC classifications of ICD10 and ICD9 codes. Lupus was identified as a cause of death if ICD10 code M32.X or L93.0, or ICD9 code 695.X or 710.0 was listed on the death record.

There were 207 death records identified by matching the NDI data elements and the date of death on the certificate to the date of death reported by the family. Analysis of these 207 records provided the following set of criteria that identified additional death records from the remaining 1,079 patients lost to follow up: 1) date of death occurred after the patient was lost to follow up; 2) at least six out of seven data elements sent to NDI matched those on the death record; and 3) EITHER lupus was listed as a cause of death on the death record OR the state of residence matched the state listed on the death record. Using these criteria, an additional 297 death records were found (Table 1).

Results: The leading primary causes of death listed on the death certificate were: lupus (n=116, 23%), cardiovascular (n=114, 23%), cancer (n=74, 15%), infection (n=66, 13%), other (n=55, 11%), respiratory (n=28, 6%), accidental (n=17, 3%), renal (n=9, 2%) and gastrointestinal (n=8, 2%). Lupus deaths and accidental deaths occurred at a significantly younger age (p-values less than 0.05 for paired t-tests; Figure 1). African-Americans died at a younger age compared to Caucasians (50 ± 15 years vs 58 ± 16 years, p< 0.001). African-Americans had a higher proportion of deaths from infections and renal causes compared to Caucasians (p=0.0017 Likelihood ratio test; Figure 2).

Conclusion: SLE patients died at an average of 55 years of age for all causes of death (compared to life expectancies of >80 years for females in the US), with lupus and cardiovascular disease identified as the leading causes of death on death certificates. Cancer and infection were the third and fourth causes of death. African-Americans died younger than Caucasians and had more infection and renal causes of death. Only respiratory deaths were significantly more common in Caucasians.

Supporting image 1

Table 1 – Matching Criteria for Death Records

Supporting image 2

Figure 1 – Age at Death versus Cause of Death

Supporting image 3

Figure 2: Cause of Death for Caucasians versus African-Americans


Disclosures: M. Petri, Exagen, AstraZeneca, Alexion, Amgen, AnaptysBio, Argenx, Aurinia, Biogen, Caribou Biosciences, CVS Health, EMD Serono, Eli Lilly, Emergent Biosolutions, GlaxoSmithKline (GSK), IQVIA, Janssen, Kira Pharmaceuticals, MedShr, Sanofi, SinoMab, Thermofisher, BPR Scientific Advisory Committee; J. Levy, Janssen; U. Sbarigia, Janssen; D. Goldman, None.

To cite this abstract in AMA style:

Petri M, Levy J, Sbarigia U, Goldman D. All-Cause Mortality in a Systemic Lupus Erythematosus Cohort [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/all-cause-mortality-in-a-systemic-lupus-erythematosus-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/all-cause-mortality-in-a-systemic-lupus-erythematosus-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology